Although this study did not categorize/emphasize molecular subtypes (ER/PR/HER2 status), nervertheless we observed serum Shh and IL-6 levels were detected mostly in ER/PR-negative patients, commonly known as triple negative breast cancer (TNBC), implying that serum Shh and IL-6 could be additionally used to monitor predictive therapeutic response. This evidence concerns the gene SHH and triple-negative breast carcinoma.